Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heart failure in women.

David H Silber1

  • 1Division of Cardiology, Penn State College of Medicine, Milton S. Hershey Medical Center, PA 17033, USA. dsilber@psu.edu

Current Women'S Health Reports
|March 12, 2003
PubMed
Summary

Women are underrepresented in heart failure clinical trials, despite experiencing the condition equally to men. Understanding gender differences in heart failure is crucial for effective treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes of cardiac transplantation for peri-partum cardiomyopathy: a multiinstitutional analysis.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantationยท2007
See all related articles

Area of Science:

  • Cardiology
  • Clinical Trials
  • Gender Medicine

Background:

  • Congestive heart failure (CHF) is a significant health concern with high morbidity and mortality.
  • Women are equally affected by heart failure but historically underrepresented in clinical trials.
  • Gender-specific differences exist in CHF clinical presentation, comorbidities, and cardiac response to injury.

Purpose of the Study:

  • To highlight the disparity of women's representation in heart failure trials.
  • To discuss the clinical implications of gender differences in heart failure.
  • To review pharmacologic treatments for systolic and diastolic heart failure, considering gender-specific factors.

Main Methods:

  • Review of existing literature on heart failure clinical trials and gender differences.
  • Analysis of clinical features, comorbidities, and cardiac remodeling in men versus women with heart failure.
  • Evaluation of pharmacologic agents for systolic heart failure (ACE inhibitors, beta-blockers, digoxin, aldosterone inhibitors).
  • Discussion of treatment guidelines for diastolic heart failure.

Main Results:

  • Women are underrepresented in heart failure trials, impacting treatment decisions.
  • Significant gender differences observed in age of onset, comorbidities, and cardiac response to injury.
  • Pharmacologic treatments for systolic failure and guidelines for diastolic failure are reviewed in the context of these differences.

Conclusions:

  • Addressing the underrepresentation of women in clinical trials is essential.
  • Understanding and incorporating gender-specific differences into heart failure management is critical for improving patient outcomes.
  • Further research is needed to fully elucidate the clinical implications of gender on heart failure pathophysiology and treatment efficacy.

Related Experiment Videos